Table 3 Outcomes of other efficacy endpoints investigated in the meta-analysis in the overall population and in the normal and poor response subgroups (difference between r-hFSH plus r-hLH and r-hFSH alone groups; ITT population)

0.02 (−0.29 to 0.33)^a

0.69 (0.12 to 1.25)^a

−0.28 (−0.66 to 0.10)^a

0.09 (−0.11 to 0.30)^a

0.34 (−0.05 to 0.73)^a

−0.01 (−0.27 to 0.25)^a

0.09 (0.01 to 0.17)^a

0.27 (0.07 to 0.47)^a

0.05 (−0.05 to 0.15)^a

0.26 (0.16 to 0.36)^a

0.43 (0.26 to 0.06)^a

0.17 (0.05 to 0.29)^a

0.24 (0.06 to 0.42)^a

0.21 (−0.12 to 0.54)^a

0.26 (0.03 to 0.48)^a

−0.23 (−0.50 to 0.05)^a

−0.51 (−1.15 to 0.12)^a

−0.15 (−0.49 to 0.18)^a

−0.11 (−0.22 to 0.00)^a

−0.38 (−0.59 to −0.17)^a

−0.06 (−0.16 to 0.04)^a

1.25 (1.13 to 1.38)^b

1.38 (1.06 to 1.80)^b

1.22 (1.04 to 1.42)^b

1.14 (1.05 to 1.25)^b

1.36 (1.04 to 1.79)^b

1.13 (1.00 to 1.27)^b

1.11 (1.01 to 1.21)^b

1.30 (0.95 to 1.78)^b

1.10 (0.94 to 1.29)^b